Fluidigm Corp
F:FLB
Fluidigm Corp
Interest Expense
Fluidigm Corp
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluidigm Corp
F:FLB
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Interest Expense
$1.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
|
Danaher Corp
NYSE:DHR
|
Interest Expense
$265m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Waters Corp
NYSE:WAT
|
Interest Expense
$50.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Interest Expense
$729m
|
CAGR 3-Years
21%
|
CAGR 5-Years
12%
|
CAGR 10-Years
22%
|
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
